Chembio Diagnostics Reports Preliminary Fourth Quarter and Full Year 2018 Revenue

Tailwinds' Take: solid guidance for the Q is well ahead of street forecasts.  MEDFORD, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care...

Chembio Diagnostics Announces 2019 Analyst and Investor Meeting

MEDFORD, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will host...

Chembio Diagnostics Receives CE Mark for Point-of-Care Diagnostic Test Developed in Collaboration with...

MEDFORD, N.Y., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has received...

Chembio Diagnostics Announces Pricing of its Public Offering of Common Stock

MEDFORD, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(NASDAQ: CEMI) (“Chembio”), a provider of point-of-care diagnostic tests for infectious diseases, announced today the pricing of...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.